Effect of dapagliflozin with and without acipimox on insulin sensitivity and insulin secretion in T2DM males

Journal of Clinical Endocrinology and Metabolism

Volumn 101, Issue 3, 2016, Pages 1249-1256

  Merovci, Aurora ^a   Abdul Ghani, Muhammad ^a   Mari, Andrea ^b   Solis Herrera, Carolina ^a   Xiong, Juan ^a   Daniele, Giuseppe ^a   Tripathy, Devjit ^a   DeFronzo, Ralph A ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b CNR   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACIPIMOX; DAPAGLIFLOZIN; FATTY ACID; GLUCAGON; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; INSULIN; METFORMIN; SODIUM GLUCOSE COTRANSPORTER 2; 2-(3-(4-ETHOXYBENZYL)-4-CHLOROPHENYL)-6-HYDROXYMETHYLTETRAHYDRO-2H-PYRAN-3,4,5-TRIOL; ANTILIPEMIC AGENT; BENZHYDRYL DERIVATIVE; GLUCOSE BLOOD LEVEL; GLUCOSIDE; PYRAZINE DERIVATIVE;

ADULT; ARTICLE; BODY MASS; CELL FUNCTION; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE DURATION; FATTY ACID BLOOD LEVEL; GLOMERULUS FILTRATION RATE; GLUCAGON BLOOD LEVEL; GLUCOSE BLOOD LEVEL; GLUCOSURIA; HUMAN; HYPERINSULINEMIC-EUGLYCEMIC CLAMP TECHNIQUE; INSULIN BLOOD LEVEL; INSULIN RELEASE; INSULIN SENSITIVITY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL GLUCOSE TOLERANCE TEST; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; AGED; BLOOD; CLINICAL TRIAL; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; GLUCOSE CLAMP TECHNIQUE; GLUCOSE TOLERANCE TEST; INSULIN RESISTANCE; METABOLISM; MIDDLE AGED; SECRETION (PROCESS); YOUNG ADULT;

ADULT; AGED; BENZHYDRYL COMPOUNDS; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; GLUCOSE CLAMP TECHNIQUE; GLUCOSE TOLERANCE TEST; GLUCOSIDES; HUMANS; HYPOLIPIDEMIC AGENTS; INSULIN; INSULIN RESISTANCE; INSULIN-SECRETING CELLS; MALE; MIDDLE AGED; PYRAZINES; YOUNG ADULT;

EID: 84960849127     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2015-2597     Document Type: Article

References (28)

1. Defronzo RA. Banting Lecture. From the triumvirateto the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes. 2009;58:773-795.
2. De Fronzo RA. Pathogenesis of type II diabetes: metabolic and molecular implications for identifying diabetes genes. Diabetes Rev. 1997;5:177-269.
3. Bays H, Mandarino L, De Fronzo RA. Role of the adipocyte, free fatty acids, and ectopic fat in pathogenesis of type 2 diabetes mel-litus. J Clin Endocrinol Metab. 2004;89:463-478.
4. Belfort R, Mandarino L, Kashyap S, et al. Dose-response effect of elevated plasma free fatty acid on insulin signaling. Diabetes. 2005; 54:1640-1648.
5. Kashyap S, Belfort R, Gastaldelli A, et al. A sustained increase in plasma free fatty acids impairs insulin secretion in nondiabetic subjects genetically predisposed to develop type 2 diabetes. Diabetes. 2003;52:2461-2474.
6. Bajaj M, Suraamornkul S, Romanelli A, et al. Effect of a sustained reduction in plasma free fatty acid concentration on intramuscular long-chain fatty acyl-Co As and insulin action in type 2 diabetic patients. Diabetes. 2005;54:3148-3153.
7. Daniele G, Eldor R, Merovci A, et al. Chronic reduction of plasma free fatty acid improves mitochondrial function and whole-body insulin sensitivity in obese and type 2 diabetic individuals. Diabetes. 2014;63:2812-2820.
8. Santomauro AT, Boden G, Silva ME, et al. Overnight lowering of free fatty acids with acipimox improves insulin resistance and glucose tolerance in obese diabetic and nondiabetic subjects. Diabetes. 1999;48:1836-1841.
9. Cusi K, Kashyap S, Gastaldelli A, Bajaj M, Cersosimo E. Effects on insulin secretion and insulin action of a 48-h reduction of plasma free fatty acids with acipimox in nondiabetic subjects genetically predisposed to type 2 diabetes. Am J Physiol Endocrinol Metab. 2007; 292:E1775-E1781.
10. Qvigstad E, Mostad IL, Bjerve KS, Grill VE. Acute lowering of circulating fatty acids improves insulin secretion in a subset of type 2 diabetes subjects. Am J Physiol Endocrinol Metab. 2003;284: E129-E137.
11. Rossetti L, Giaccari A, De Fronzo RA. Glucose toxicity. Diabetes Care. 1990;13:610-630.
12. Del Prato S, Leonetti F, Simonson DC, Sheehan P, Matsuda M, De Fronzo RA. Effect of sustained physiologic hyperinsulinaemia and hyperglycaemia on insulin secretion and insulin sensitivity in man. Diabetologia. 1994;37:1025-1035.
13. Boden G, Ruiz J, Kim CJ, Chen X. Effects of prolonged glucose infusion on insulin secretion, clearance, and action in normal subjects. Am J Physiol. 1996;270:E251-E258.
14. Solomon TP, Knudsen SH, Karstoft K, Winding K, Holst JJ, Ped-ersen BK. Examining the effects of hyperglycemia on pancreatic endocrine function in humans: evidence for in vivo glucotoxicity. J Clin Endocrinol Metab. 2012;97:4682-4691.
15. Merovci A, Solis-Herrera C, Daniele G, et al. Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production. J Clin Invest. 2014;124:509-514.
16. Ferrannini E, Muscelli E, Frascerra S, et al. Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. J Clin Invest. 2014;124:499-508.
17. Polidori D, Mari A, Ferrannini E. Canagliflozin, a sodium glucose co-transporter 2 inhibitor, improves model-based indices of β-cell function in patients with type 2 diabetes. Diabetologia. 2014;57: 891-901.
18. Abdul-Ghani MA, Matsuda M, Jani R, et al. The relationship between fasting hyperglycemia and insulin secretion in subjects with normal or impaired glucose tolerance. Am J Physiol Endocrinol Metab. 2008;295:E401-E406.
19. Kanat M, Mari A, Norton L, et al. Distinct β-cell defects in impaired fasting glucose and impaired glucose tolerance. Diabetes. 2012;61: 447-453.
20. Wright EM, Loo DD, Hirayama BA. Biology of human sodium glucose transporters. Physiol Rev. 2011;91:733-794.
21. Mari A, Tura A, Gastaldelli A, Ferrannini E. Assessing insulin secretion by modeling in multiple-meal tests: role of potentiation. Diabetes. 2002;51(suppl 1):S221-S226.
22. Abdul-Ghani MA, Norton L, Defronzo RA. Role of sodium-glucose cotransporter 2 (SGLT 2) inhibitors in the treatment of type 2 diabetes. Endocr Rev. 2011;32:515-531.
23. Rossetti L, Smith D, Shulman GI, Papachristou D, De Fronzo RA. Correction of hyperglycemia with phlorizin normalizes tissue sensitivity to insulin in diabetic rats. J Clin Invest. 1987;79:1510-1515.
24. Lindmark S, Burén J, Eriksson JW. Insulin resistance, endocrine function and adipokines in type 2 diabetes patients at different gly-caemic levels: potential impact for glucotoxicity in vivo. Clin Endocrinol (Oxf). 2006;65:301-309.
25. Burén J, Lindmark S, Renström F, Eriksson JW. In vitro reversal of hyperglycemia normalizes insulin action in fat cells from type 2 diabetes patients: is cellular insulin resistance caused by glucotoxicity in vivo? Metabolism. 2003;52:239-245.
26. Zierath JR, Galuska D, Nolte LA, Thörne A, Kristensen JS, Wall-berg-Henriksson H. Effects of glycaemia on glucose transport in isolated skeletal muscle from patients with NIDDM: in vitro reversal of muscular insulin resistance. Diabetologia. 1994;37:270-277.
27. Fulcher GR, Walker M, Farrer M, Johnson AS, Alberti KG. Acipimox increases glucose disposal in normal man independent of changes in plasma nonesterified fatty acid concentration and whole-body lipid oxidation rate. Metabolism. 1993;42:308-314.
28. Bonner C, Kerr-Conte J, Gmyr V, et al. Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic a cells triggers glucagon secretion. Nat Med. 21:512-517.